BeiGene names chief medical officer, immuno-oncology
Prior to joining BeiGene, Dr. Peterson was Vice President of Clinical Development at Medivation, where she was primarily responsible for the development of enzalutamide and talazoparib in breast cancer and of pidilizumab in diffuse large b-cell lymphoma.
Previously, she served as Associate Group Medical Director at Genentech, where she was responsible for the development of early stage molecules targeting multiple major pathways in oncology.
Prior to joining Genentech, Dr. Peterson was an Instructor of Medicine in Oncology at the University of Chicago, where she conducted translational research in tumor immunology in conjunction with Dr. Thomas F. Gajewski.
Dr. Peterson received her M.D. from Thomas Jefferson University in Philadelphia, PA, and she completed her residency in Internal Medicine at Northwestern Memorial Hospital and Fellowship in Hematology and Oncology at the University of Chicago.
She holds a Bachelor of Arts degree from Wesleyan University in Middletown, CT.
Dr. Eric Hedrick, currently serving as the Interim Chief Medical Officer, will continue to oversee global clinical hematology development including the program for BGB-3111, BeiGene’s BTK inhibitor, and will remain serving as an advisor as BeiGene continues to expand its global clinical development capabilities. ■
LATEST MOVES FROM Massachusetts
- RXI Pharma names Gerrit Dispersyn chief development officer
- resTORbio appoints Joan Mannick as CMO
- C&W Services appoints Mike Losier as director
- Charles River Associates appoints Robert A. Whitman to board
- Ironwood Pharmaceuticals appoints Christopher Wright as SVP
More inside POST
Motivate, motivate, motivate Leadership
Personal and company's vision debunked Leadership